Blake Beehler
About Blake Beehler
Blake Beehler is the Executive Director of Nonclinical Quality at Bristol Myers Squibb, with over 30 years of experience in the pharmaceutical industry.
Title and Role at Bristol Myers Squibb
Blake Beehler is currently employed at Bristol Myers Squibb as the Executive Director of Nonclinical Quality. In this role, Blake is responsible for the quality strategy, governance, and auditing within the Nonclinical Quality function in R&D Quality. The position also involves overseeing quality management systems that support strategies and technologies essential for nonclinical research and development.
Educational Background
Blake Beehler studied at the University at Buffalo, where Blake achieved a Master of Science (MS) in Natural Sciences/Pharmacology. This educational foundation has provided Blake with robust knowledge and expertise necessary for the ongoing success and leadership in the pharmaceutical industry.
Professional Experience in the Pharmaceutical Industry
Blake Beehler holds over 30 years of experience in the pharmaceutical industry, beginning a career as a Research Scientist in Drug Discovery in 1990. Blake has since climbed the career ladder, taking on roles of increasing responsibility in Global Quality from 2005 to 2016. In addition, Blake worked as a Clinical Scientist in Clinical Development from 2004 to 2005.
Nonclinical Quality Leadership
As the leader of the Nonclinical Quality function within R&D Quality at Bristol Myers Squibb, Blake Beehler is charged with the quality strategy, governance, and auditing of nonclinical processes. This includes overseeing compliance with FDA-Good Laboratory Practices, Animal Welfare Practices, and other relevant regulations in nonclinical laboratory safety studies. Additionally, Blake manages quality risk at both organizational and process levels to guide audit focus.
Regulatory Compliance and Risk Management
In the role at Bristol Myers Squibb, Blake Beehler is responsible for handling regulatory agency inspections and providing consulting on regulatory requirements. This includes ensuring compliance with standards such as FDA-Good Laboratory Practices and Animal Welfare Practices. Blake also audits processes related to biomarker and companion diagnostics development and oversees the use of DEA-regulated controlled substances for research purposes.